Drug intelligence / Profile preview

QRX002

Development stage: Preclinical
Lead developer: Quoin Pharmaceuticals
Modality: Small Molecules
Administration: Transdermal

Overview

**QRX002** is a once-daily transdermal formulation of an NMDA receptor antagonist developed by Quoin Pharmaceuticals for treating suicidal ideation, particularly in military veterans with PTSD. It aims to address a major unmet need in this population, potentially qualifying for Orphan Drug and Breakthrough Therapy designations. The program was proposed around 2017-2019 but remains at the preclinical stage with no reported clinical trial data or further advancement.[1][4][7][10]

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on QRX002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QRX002.

Explore the full profile